-transparent.png){kind=logo}
The main progress in the management of soft tissue sarcomas have been obtained in the field of local control. Although the main evolutive, vital, risk of these diseases is metastatic dissemination, efficacy of adjuvant chemotherapy remains a controversial issue. Thus, adjuvant chemotherapy cannot be considered as a standard for any situation. The last results of clinical trials, meta-analysis and population studies are presented and discussed in this article. New therapeutic strategies are to be developed to prevent metastases in soft tissue sarcomas. This needs a better understanding of the biology of those tumors, of metastases risk factors and of the determinants of systemic therapies efficacy in these tumors.
B Bui-Nguyen, and
A Italiano, and
F Delva, and
M Toulmond
November 2000,
Current oncology reports,
B Bui-Nguyen, and
A Italiano, and
F Delva, and
M Toulmond
January 1997,
Cancer treatment and research,
B Bui-Nguyen, and
A Italiano, and
F Delva, and
M Toulmond
January 1993,
Cancer treatment and research,
B Bui-Nguyen, and
A Italiano, and
F Delva, and
M Toulmond
January 1989,
Cancer treatment and research,
B Bui-Nguyen, and
A Italiano, and
F Delva, and
M Toulmond
April 2012,
Surgical oncology clinics of North America,
B Bui-Nguyen, and
A Italiano, and
F Delva, and
M Toulmond
April 1995,
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
B Bui-Nguyen, and
A Italiano, and
F Delva, and
M Toulmond
March 1980,
Schweizerische medizinische Wochenschrift,
B Bui-Nguyen, and
A Italiano, and
F Delva, and
M Toulmond
August 1995,
Hematology/oncology clinics of North America,
B Bui-Nguyen, and
A Italiano, and
F Delva, and
M Toulmond
January 1991,
Cancer treatment and research,
B Bui-Nguyen, and
A Italiano, and
F Delva, and
M Toulmond
March 1993,
New York state journal of medicine,
